Adrienne M. Gilligan

Dr. Adrienne M. Gilligan


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2024 in ESMO Open
Verified
Journal Article
Open access
LRL.E. Raez
L.E. Raez
HKHyunseok Kang
Hyunseok Kang
YOY. Ohe
Y. Ohe
MKM. Khanal
M. Khanal
YHY. Han
Y. Han
AGAdrienne M. Gilligan
Adrienne M. Gilligan
This post-hoc retrospective study describes long-term patient-reported outcomes (PROs) for REarranged during Transfection (RET)-altered non-small-cell lung cancer (NSCLC), medullary thyroid cancer (MTC), non-MTC thyroid cancer (TC), and tumor agnostic (TA) patients (Data cut-off: January 2023) from the LIBRETTO-001 trial. Patients completed the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30). Patients with MTC also completed a modified version of the Systemic Therapy-Induced Diarrhea Assessment Tool (mSTIDAT). The proportion of patients with improved, stable, or worsened status after baseline was reported. PROs were summarized at 3 years (cycle 37) post-baseline for the NSCLC and MTC cohorts, and at 2 years (cycle 25) post-baseline for the TC and TA cohorts. Time-to-event outcomes (time to first improvement or worsening and duration of improvement) were reported. The baseline assessment was completed by 200 (63.3%), 209 (70.8%), 50 (76.9%), and 38 (73.1%) patients in the NSCLC, MTC, TC, and TA cohorts, respectively. The total compliance rate was 80%, 82%, 70%, and 85%, respectively. Approximately 75% (NSCLC), 81% (MTC), 75% (TC), and 40% (TA) of patients across all cohorts reported improved or stable QLQ-C30 scores at year 3 (NSCLC and MTC) or year 2 (TC and TA) with continuous selpercatinib use. Across cohorts, the median time to first improvement ranged from 2.0 to 19.4 months, the median duration of improvement ranged from 1.9 to 28.2 months, and the median time to first worsening ranged from 5.6 to 44.2 months. The total compliance rate for the mSTIDAT was 83.7% and the proportion of patients with MTC who reported diarrhea on the mSTIDAT was reduced from 80.8% at baseline to 35.6% at year 3. A majority of patients with RET-driven cancers improved or remained stable on most QLQ-C30 domains, demonstrating favorable health-related quality of life as measured by the QLQ-C30 during long-term treatment with selpercatinib.

27 December 2023 in Cancers
Verified
Journal Article
Open access
PDF file
FBF. De Braud
F. De Braud
BDBarbara Deschler-Baier
Barbara Deschler-Baier
JMJohn C. Morris
John C. Morris
FWFrancis Worden
Francis Worden
YHYimei Han
Yimei Han
AGAdrienne M. Gilligan
Adrienne M. Gilligan
Selpercatinib is indicated for locally advanced/metastatic RET-activated solid tumors after progression or following prior systemic therapies. Until the recently published data from LIBRETTO-431 and LIBRETTO-531, there were limited effectiveness data comparing selpercatinib with other first-line treatments in RET-activated non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and thyroid cancer (TC). This study analyzed patient data from LIBRETTO-001 and compared the outcomes (time to treatment discontinuation {TTD}, time to next treatment or death {TTNT-D}, time to progression {TTP}, and the objective response rate {ORR}) of first-line selpercatinib (selpercatinib arm) use with the outcomes of first-line standard therapies in patients who then received selpercatinib in later lines of treatment (comparator arm). Overall, the first-line selpercatinib arm had a longer TTD, TTNT-D, and TTP versus the first-line comparator arm. The hazard ratios (HRs) for TTD were 0.29 (NSCLC), 0.15 (MTC), 0.08 (TC); for TTNT-D, the HRs were 0.48 (NSCLC), 0.11 (MTC), 0.09 (TC); and for TTP, the HRs were 0.54 (NSCLC), 0.15 (MTC), and 0.12 (TC). The ORR was higher for first-line selpercatinib versus the first-line comparator (NSCLC: 85.3% vs. 39.7%; MTC: 82.6% vs. 15.2%; and TC: 81.8% vs. 31.8%). First-line selpercatinib use is associated with improved outcomes compared to first-line comparator therapies for patients with advanced/metastatic RET-activated cancers.

28 March 2025 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
MMMelina E. Marmarelis
Melina E. Marmarelis
AGAdrienne M. Gilligan
Adrienne M. Gilligan
TSTomoko Sugihara
Tomoko Sugihara
SZShen Zheng
Shen Zheng
TMTyler Marquart
Tyler Marquart
CACharu Aggarwal
Charu Aggarwal
"HSR25-167: Real-World Study Demonstrates Lack of Biomarker-driven Care in First-Line Treatment for Advanced/Metastatic Non-Small Cell Lung Cancer That Received Next-Generation Sequencing Testing" published on 28 Mar 2025 by National Comprehensive Cancer Network.

16 July 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MMMelina Marmarelis
Melina Marmarelis
AGAdrienne M. Gilligan
Adrienne M. Gilligan
TSTomoko Sugihara
Tomoko Sugihara
TMTyler Marquart
Tyler Marquart
SWSamuel Whipple
Samuel Whipple
CACharu Aggarwal
Charu Aggarwal
Background: Next-generation sequencing (NGS) and the initiation of biomarker-driven first-line (1L) treatment on overall survival (OS) was evaluated in advanced/metastatic non-small-cell lung cancer (a/mNSCLC). By applying a time-dependent regression modeling approach accounting for fluidity of clinical care, this study aimed to capture the dynamic interplay between NGS testing, turnaround time (TaT), treatment decisions and timing of initiation, and outcomes more comprehensively than traditional static analyses. Methods: This study was a retrospective observational study using the US Flatiron Health EHR-derived de-identified database. Eligible adults had non-squamous a/mNSCLC and received blood-based (B-NGS) or tissue-based (T-NGS) NGS within 90 days of diagnosis (1 January 2018–30 June 2023). A time-dependent covariate captured the NGS TaT, presence of a targetable alteration, time to 1L initiation, and 1L regimen (targeted concordant vs. discordant). OS was measured from the NGS order date to death. Results: A total of 1806 patients underwent B-NGS and 2583 underwent T-NGS. Starting empiric discordant 1L therapy before NGS results was associated with higher mortality versus initiating targeted concordant therapy after biomarker identification: B-NGS hazard ratio (HR): 1.58 (95% CI, 1.10–2.26); T-NGS HR: 1.07 (0.82–1.39). Considering discordant 1L therapy irrespective of timing, mortality remained higher versus targeted concordant therapy: B-NGS HR: 1.35 (1.04–1.74); T-NGS HR: 1.24 (0.98–1.56). Conclusions: This study demonstrates that waiting for comprehensive molecular profiling results before starting 1L treatment enables the delivery of appropriate biomarker-driven therapy, which translates into improved patient outcomes. Delays in NGS result availability or treatment initiation were linked to worse survival, underscoring the need for streamlined diagnostic workflows and rapid testing modalities.

22 April 2026 in Cancer Treatment and Research Communications
Verified
Journal Article
Open access
MMMelina Marmarelis
Melina Marmarelis
AGAdrienne M. Gilligan
Adrienne M. Gilligan
TSTomoko Sugihara
Tomoko Sugihara
SZShen Zheng
Shen Zheng
TMTyler Marquart
Tyler Marquart
CACharu Aggarwal
Charu Aggarwal
This study examined treatment patterns among patients with available next generation sequencing (NGS) results before starting first-line (1L) treatment, using either tissue-based (T-NGS) or blood-based (B-NGS) NGS testing in patients with advanced/metastatic non-small cell lung cancer (a/mNSCLC). This retrospective study included US patients aged ≥18 years with a/mNSCLC who received a T-NGS or B-NGS test and had results available prior to 1L. Most frequent (n ≥ 40) treatment patterns were reported as sequence of treatments received in 1L through (→) second line (2L). Overall survival (OS) was measured from the date of NGS test result. Descriptive analyses were conducted separately in T-NGS and B-NGS, stratified by biomarker status. A total of 2980 (T-NGS, 1632; B-NGS, 1348) patients were eligible. The median age was 71 years, 52% female, 62% White, and 83% smokers. Approximately 32% (T-NGS, 35%; B-NGS, 32%) of patients were positive for biomarkers and receipt of targeted therapy (TT) in 1L was ≤68% (T-NGS, 67%; B-NGS, 70%). Median OS was longest for 'TT → none' in the biomarker-positive subgroups of both cohorts. Approximately 30% of patients with biomarker-positive disease did not receive the indicated 1L guideline-recommended TT despite availability of NGS test results prior to 1L initiation. These findings highlight variability in 1L treatment selection for patients with biomarker-positive a/mNSCLC and underscore the need for further research to understand barriers to TT use. Health systems should consider proactive, scalable solutions (e.g., EHR-based alerts) to ensure that biomarker-driven treatment is not just possible but reliably delivered.